Prot ocol Version 3  8 August 2 016 1 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase 2a Study of Interferon Gamma -1b for the 
Treatment of Autosomal Dominant Type 2 
Osteopetrosis  
 
Michael Econs , MD  
Indiana  Univ ersity S chool  of Medicine D epartment of Endocrinology and Metabolism  
1120 West Michigan Street Room 459  
Indianapolis, IN 46202 
Prot ocol Version 3  8 August 2 016 2 
 
  
 
 
Phase 2a Study of Interferon Gamma -1b for the 
Treatment of Autosomal Dominant Type 2 Osteopetrosis  
 
Protocol # 1510340687  
Version 3 (8 August  2016)  
IND # 128455  
NCT# 02584608  
 
 
 
 
Protocol  Physician  (Sponsor -investigator)  
 
Michael J. Econs, MD  
Glenn W. Irwin, Jr., Professor of Endocrinology and Metabolism  
Director: Division of Endocrinology and Metabolism  
Professor of Medicine and Medical and Molecular Genetics  
Indiana University School of Medicine  
Endocrinology Service Line Leaders, Indiana University Health Physicians  
1120 W. Michigan Street  
Gatch Clinica l Building CL 459  
Indianapolis, IN 46202  
Tel:  317-274 -1339  
Fax: 317-278 -0658  
Email: mecons@iu.edu  
 
 
 
 
This document is confidenti al.  It is provided for review only to investigator s, study staff, safety 
monitoring boards,  and the institut ional review board . 
Prot ocol Version 3  8 August 2 016 3 
 
  
 
 
PROTOCOL SIGNATURE PAGE 
 
The sign ature below constitutes  the approval of this pro tocol  and the  attachm ents, and 
provid es the ne cessary assurances that  this trial will be condu cted according  to all stipul ations 
of the protocol,  including  all statements  regarding confidenti ality, and according  to local legal 
and regu latory requirem ents and appli cable U.S. federal regulations  and ICH gu idelines. 
 
 
 
The Lead Principal Inv estigator should  sign below. 
 
Princip al Inve stigator:    Michael J Econ s, M.D.    
 
 
_________________________________________ _____________________ ____ Date __ _______ _________________  
Name / Title  
The original sign ature pages should be filed  with I ndiana University. A copy of this signature 
page should be maintained at each site in t he regulatory binder. 
  
Prot ocol Version 3  8 August 2 016 4 
 
 Contents  
1.0 ‚Äì OVERVIEW A ND BACKGROUND  ................................ ................................ ................................ ................................ .. 7 
1.1 BACKG ROUND ................................ ................................ ................................ ................................ ............................  7 
1.2 PRECLINICAL AND CLINICAL EXPERIENCE ................................ ................................ ................................ ... 8 
1.3 SCIENTIFIC RATIONALE  ................................ ................................ ................................ ................................ .........  8 
2.0 ‚Äì OBJECTIV ES ................................ ................................ ................................ ................................ ................................ ..........  9 
2.1 PRIMARY  OBJECTIVE ................................ ................................ ................................ ................................ ...............  9 
2.2 SECOND ARY  OBJECTIVES ................................ ................................ ................................ ................................ ...... 9 
2.3 SAFETY OBJECTIVE  ................................ ................................ ................................ ................................ .........................  9 
3.0 ‚Äì STUDY DESIGN................................ ................................ ................................ ................................ ................................ ..... 9 
3.1 STUDY DESCRIPTION  ................................ ................................ ................................ ................................ ..............  9 
3.2 STUDY  DURA TION ................................ ................................ ................................ ................................ .................  10 
3.3       ENROLLMENT  ................................ ................................ ................................ ................................ ..........................  10 
3.4       STUDY ENDPOINTS  ................................ ................................ ................................ ................................ ................  10 
Primary Efficacy Endpoint  ................................ ................................ ................................ ................................ ...........  10 
Secondary Efficacy Endpoints  ................................ ................................ ................................ ................................ ..... 10 
Safety Endpoints  ................................ ................................ ................................ ................................ ...............................  10 
3.5   ONGO ING SAFETY REVIEW ................................ ................................ ................................ ................................ .... 11 
3.6    STUDY  RISKS ................................ ................................ ................................ ................................ ................................  11 
Risks of Taking Actimmune  ................................ ................................ ................................ ................................ .........  11 
Radiation  ................................ ................................ ................................ ................................ ................................ ..............  12 
Risk of Blood Draws ................................ ................................ ................................ ................................ ........................  12 
Loss of Confidentiality ................................ ................................ ................................ ................................ ....................  12 
3.7 STUDY  BENEFITS ................................ ................................ ................................ ................................ ...................  12 
3.8 INCLUSION  OF CHILDR EN ................................ ................................ ................................ ................................ .. 12 
4.0 ‚Äì STUDY MEDICATI ON ................................ ................................ ................................ ................................ ......................  13 
4.1 STRUCTURE  AND NOMENCLATURE  ................................ ................................ ................................ ..............  13 
4.2 PHYSICAL PROPERTIES ................................ ................................ ................................ ................................ ....... 13 
4.3 MECHANISM OF ACTION ................................ ................................ ................................ ................................ ..... 13 
Pharmacokinetics  ................................ ................................ ................................ ................................ .............................  13 
4.4 STUDY  RELA TED INFO RMATION ................................ ................................ ................................ ....................  14 
Contraindications  ................................ ................................ ................................ ................................ .............................  14 
Precautions  ................................ ................................ ................................ ................................ ................................ .........  14 
5.0 ‚Äì ELIGIBILITY  ................................ ................................ ................................ ................................ ................................ ....... 14 
5.1 INCLUSION CRITERIA ................................ ................................ ................................ ................................ ...........  14 
5.2 EXCLUSION CRITERIA ................................ ................................ ................................ ................................ ..........  14 
Prot ocol Version 3  8 August 2 016 5 
 
 5.3 EARLY  TERMINATION OF A STUDY  PARTICIPANT ................................ ................................ .................  15 
6.0 ‚Äì STUDY P ROCEDURES  ................................ ................................ ................................ ................................ .....................  17 
6.1 INFORMED CONSENT  ................................ ................................ ................................ ................................ ..................  17 
6.2 PHYS ICAL EXAM  ................................ ................................ ................................ ................................ ............................  17 
6.3 VITAL SIGNS  ................................ ................................ ................................ ................................ ................................ .... 17 
6.4 ADVERSE EVENTS  ................................ ................................ ................................ ................................ .........................  17 
6.5 CONCOMITANT MEDICATIONS  ................................ ................................ ................................ ...............................  18 
6.6 RENAL ULTRASOUND  ................................ ................................ ................................ ................................ .................  18 
6.7 HEIGHT, WEIGHT AND BSA  ................................ ................................ ................................ ................................ ...... 18 
6.8 STUDY DRUG  ................................ ................................ ................................ ................................ ................................ ... 18 
Study medication diary  ................................ ................................ ................................ ................................ ..................  19 
Compliance  ................................ ................................ ................................ ................................ ................................ .........  20 
6.9       LAB COLLECTION ................................ ................................ ................................ ................................ ....................  20 
6.10     RADIOGRAPHS  ................................ ................................ ................................ ................................ .........................  20 
Skeletal survey radiographs  ................................ ................................ ................................ ................................ ........  20 
Duel Energy absorptiometry (DXA)  ................................ ................................ ................................ .........................  20 
Spine QCT with Volumetric Spine BMD  ................................ ................................ ................................ ..................  20 
pQCT of Radius and Tibia  ................................ ................................ ................................ ................................ .............  20 
6.11 STUDY VISIT SCHEMATIC  ................................ ................................ ................................ ................................ ....... 22 
6.12 VISIT DETAILS ................................ ................................ ................................ ................................ ..............................  24 
Scree ning ( -30 to -1) ................................ ................................ ................................ ................................ .......................  24 
Visit 1 Baseline (day 0)  ................................ ................................ ................................ ................................ ..................  24 
Visit 2 week 2/ day 14 (¬±3 day)  ................................ ................................ ................................ ................................ . 24 
Visits 3 week4(¬±3 day) and visit 5 week 11 (¬±5 day)  ................................ ................................ .......................  25 
Visit 4 week 8 (¬±5 day)  ................................ ................................ ................................ ................................ ..................  25 
Visit 6 week 14 or early termination (¬±5 day)  ................................ ................................ ................................ ..... 25 
Visit 7 week 18 Follow up (¬±3 day)  ................................ ................................ ................................ ..........................  25 
6.13      RETENTION PLAN  ................................ ................................ ................................ ................................ .................  25 
7. 0 - REPORTING OF ADVERSE E VENTS OR UNANTICI PATED PROBLEMS INVOLVING RISK TO 
PARTICI PANTS OR  OTHERS ................................ ................................ ................................ ................................ ..................  26 
7.1       UNANTICIPATED  PROBLEMS ................................ ................................ ................................ ............................  26 
7.2 DATA  SAFETY MON ITORING BOARD ................................ ................................ ................................ .............  26 
7.3 ADV ERSE EVENTS ................................ ................................ ................................ ................................ ..................  26 
8. 0 ‚Äì STATI STICAL CONSIDER ATIONS ................................ ................................ ................................ .............................  28 
9. 0 ‚Äì PRIVACY /CONFIDENTIALIT Y ISSUES ................................ ................................ ................................ ....................  29 
10.0 F O L LO W -UP AND RECORD RETENT ION ................................ ................................ ................................ ............  29 
Prot ocol Version 3  8 August 2 016 6 
 
 10.1 SUBJECT COMPENSATION ................................ ................................ ................................ ................................ .. 29 
10.2 RECORD RETENTION................................ ................................ ................................ ................................ ............  29 
11.0 ‚Äì REFERENC ES CITED ................................ ................................ ................................ ................................ ....................  29 
 
 
 
 
  
Prot ocol Version 3  8 August 2 016 7 
 
 1.0 ‚Äì OVERVIEW A ND BACKGROUND  
1.1 BACKG ROUND 
Autosomal dominant Osteopetrosis type 2 (ADO2)  is a heritable osteosclerotic disorder that 
usually results from heterozygous missense mutations in the CLCN7 gene  [1, 2] , and is 
characterized by a wide range of symptoms and severity including multiple fractures, 
impaired vision and hearing, pancytopenia and osteomy elitis  [3-5].  ADO2 is presently 
incurable, although anecdotal evidence and recent studies in a murine model suggest that 
interferon gamma -1b may have beneficial effects [6]. 
ADO2 (also known as Albers -Sch√∂nberg disease and ‚Äúmarble bone disease‚Äù) is an autosomal 
dominant disorder with an incidence of 5.5 in 100,000 people and penetrance of 
approximately 66 % [2, 4] . We have kept the designation ADO2 for the disease we are 
studying because the disease caused by activating mutations in the LRP5 gene, while not 
technically an osteopetrosis, is inappropriately still referred to as ADO1 in the literature. 
Because of the in complete penetrance and a mild phenotype in some individuals with 
CLCN7  mutations, ADO2 is sometimes referred to as the "benign" form of osteopetrosis to 
distinguish it from the severe "malignant" recessive form, which is life -threatening in 
infancy. Howev er, referring to ADO2 as ‚Äúbenign‚Äù is a misnomer because most ADO2 patients 
suffer complications from their disease. In a previous study of 62 ADO2 patients, hip or 
femur fractures occurred in 16% of ADO2 children and 49% of ADO2 adults, and all 4 of the 
most severely affected patients have died from complications of osteopetrosis [4]. In the  ADO2 
population  at Indiana University , there was a high rate (19%) of severe visual loss (t hought 
to be due to lack of bone resorption to widen the optic canal during growth).  Additionally, 
16% of the  patients had osteonecrosis or osteomyelitis, and bone marrow failure occurred 
in 3% of patients [4]. Similar to these  study  results , Benichou et al [5] studied 42 ADO2 
patients and found that 78% of patients had fractures and over half had orthopedic 
procedures with half o f those having at least 3 procedures. They also documented a high 
rate of mandibular osteomyelitis (12.9%). In contrast to our study [4], only 5% had visual 
loss due to optic nerve  compression [5]. Thus, in the two largest studies to date, ADO2 
patients manifest significant, and in some cases, severe dis ease.  
Although very high dose calcitriol (up to 18 mcg per day) has been used anecdotally (L. Key, 
personal communication), this approach has not been shown to be efficacious in ADO2.  The 
only reference [7] cited on the clinical management of ADO2 in OMIM 
(http://www.omim.org/entry/166600 , accessed May 31, 2015) is a case report of a child 
with severe recessive osteopetrosis, who had a partial response to calcitriol.  Indeed, Dr. 
Econs‚Äô experience treating ADO2 patients with high dose calcitriol has not resulted in 
improvements in bone mineral density or biochemical markers of bone turnover, while 
having risk of nephrolithiasis and nephrocalcinosis. Moreover, the calcitriol studies in the 
ADO2 mouse model indicated no benefit and a poss ible worsening of the bone phenotype 
(see preliminary data). As a result, Dr. Econs  has abandoned the practice of treating ADO2 
patients with calcitriol and is currently following these patients off therapy, essentially 
observing the natural progression of  the disease.  
 
Prot ocol Version 3  8 August 2 016 8 
 
 1.2 PRECLINICAL AND CLINICAL EXPERIENCE 
The first evidence of a potentially effective therapy comes from  studies of interferon gamma 
in a novel ADO2 ‚Äúknock -in‚Äù mouse with a G213R missense mutation in the Clcn7  gene [8], 
which is syntenic to the human G215R mutat ion identif ied in several ADO2 patient families 
[2]. Mice homozygous for the G213R mutation have severe osteopetrosis, absent tooth 
eruption, and die by 4 weeks of age, which is similar to the human recessive disease caused 
by mutations in CLCN7  and several other genes [8]. Mice heterozygous for the G213R 
mutation have high whole body aBMD and bone volume per total volume ( BV/TV) at distal 
femur and increased numbers of poorly resorbing osteoclasts, resembling human ADO2 [8]. 
Although the  ADO2 mouse does not display spontaneous fractures as seen in the adult 
human disease, the fact that these mice have a 2 -fold increase in BV/TV at 12 weeks of age 
and have been successfully used to test two potential therapies, one of which results in a 
partial correction of the phenotype (see below), indicates that this model is an excellent 
model of osteoclast dysfunction.  In concert with human disease, the phenotype of our ADO2 
mice gets more pronounced w ith age.  
1.3 SCIENTIFIC RATIONALE  
Interferon gamma -1b increases bone resorption and returns the bone phenotype towards 
normal in the ADO2 mouse:  
Interferon gamma -1b (IFN -G) is used in 
patients with recessive forms of osteopetrosis 
to control disease until a donor can be found 
for BMT, whi ch has been shown beneficial in 
this very severe disorder [9].  IFN -G is not 
approved for use in ADO2, as it has never been 
tested in this disease. Moreover, cell culture 
data is inconclusive regarding whether IFN -G 
increases or decreases normal osteoclast 
development, number, and/or activity [10-17]. 
Therefore, we sought to use our newly 
developed ADO2 mouse model to test whether 
murine interferon gamma and/or high dose 
calcitriol would decrease bone mass in ADO2 mice.  
Six-week -old male and female ADO2  mice (N=10/group) were treated with vehicle, or 
calcitriol (low 0.1 ¬µg/kg, medium 0.5 
¬µg/kg, or high 1 ¬µg/kg doses) or 
interferon gamma (low 22.5 ¬µg/kg, 
medium 37.5 ¬µg/kg, or high 100 ¬µg/kg 
dose) 5 times per week for 8 weeks. Bone 
was phenotyped by DXA and micro -
computed tomography ( ¬µCT).  Serum and 
urine biochemistries and bone resorption 
markers were also analyzed. Mice treated 
with low and medium doses of calcitriol 
showed a trend of higher aBMD and 
BV/TV whereas high dose calcitriol 
significantly (p< 0.05) increased bone 

Prot ocol Version 3  8 August 2 016 9 
 
 mass compared to vehicle, indicating that calcitriol actually worsened the bone phenotype 
of ADO2 mice [6].  ADO2 mice treated with all d oses of IFN -G significantly (p<0.05) 
attenuated the increase of whole body aBMD [6] and BV/TV at the distal femur in both male 
and female mice as compared to those treated with vehicle (Figure 2A). Importantly , the 
reduction in BV/TV due to IFN -G treatment was to a level approximately half way between 
WT mice and the ADO2 mutant mice (the therapeutic midpoint), indicating that there was 
an incomplete, but meani ngful reduction in  the abnormal bone phenotype with only 8 
weeks of therapy.  Additionally, serum CTX and the CTX/TRAP ratio were increased in the 
IFN-G groups, but not in the calcitriol treated groups, indicating that there was an increase 
in bone resorpt ion with IFN -G treatment ( [6] and Figure 2B).  This study demonstrates that 
IFN-G has potential to treat human ADO2 and thes e results have led us to propose a  short -
term human trial with human Interferon gamma -1b (Actimmune¬Æ).  
2.0 ‚Äì OBJECTIV ES 
2.1 PRIMARY  OBJECTIVE 
‚Ä¢ To evaluate the effect of treatment with ACTIMMUNE at week 14 on bone resorption 
markers (i.e. C-telopeptide [ CTX], and N -telopeptide (NTX)/creatinine ratio ) in 
subject s, age 3 -65, diagnosed with Autosomal Dominant Osteopetrosis Type 2 (ADO2) 
due to heterozygous mutations in the chloride channel 7 ( CLCN7 ) gene.  
2.2 SECOND ARY  OBJECTIVES 
‚Ä¢ To evaluate the effect of ACTIMMUNE at a stable dose over a 6 to 12 week treatment 
period on bone turnover markers (tartrate -resistant acid phosphatase type 5b 
[TRAP5b] , N-telopeptide (NTX), and CTX /TRAP5b ratio) .  
‚Ä¢ To evaluate the change in CTX level from the end of treatment (Week 14 visit) to 
1 month after discontinuation of ACTIMMUNE treatment (Week 18).  
‚Ä¢ To evaluate changes in bone formation markers (P1NP and bone spe cific alkaline 
phosphatase) at Weeks 8 and 14.  
2.3 S AFETY OBJECTIVE  
‚Ä¢ To evaluate the safety and tolerability of ACTIMMUNE in ADO2 adults.  
3.0 ‚Äì STUDY DESIGN 
3.1 STUDY DESCRIPTION   
This is a single center, open -label, dose -escalation study evaluating the efficacy, as defined 
by biochemical endpoints, and safety profiles of ACTIMMUNE in ADO2 subject .   
We will treat 12 ADO2 subjects (children or adults age 3 -65) with Actimmune¬Æ via a dose 
escalation protocol to a dose of 50 ¬µg/m2 subcutaneously three times per week (TIW) for 8 
weeks.  If serum CTX does not increase by more than 25% by week 8, the dose will be 
increased to 100 ¬µg/m2 subcutaneously TIW.   
Individual subjects  in wh om ACTIMMUNE administration increases bone resorption 
markers during the 14 weeks of this trial will be eligible for a 1 year extension trial.  
Prot ocol Version 3  8 August 2 016 10 
 
 3.2 STUDY  DURA TION 
Subject involvement from screening to completion of study will be approximately 157 days 
or ap proximately 5 months.  Screening procedures can be done over a 30 day  period prior 
to baseline (day 0 ).  Stud y drug will be started on Day 0 and continued through 14 weeks.  
Subjects will be seen at the completion of the 14 weeks for end of treatment and t hen 4 
weeks later for a safety follow -up visit.  There will be 8 visits during the trial.  Six of these 
visits will occur at India na University Hospital.  Visit 3  and 5 can occur by phone with the 
coordinator and have labs collected at a local lab collecti on site.   
3.3       ENROLLMENT  
There will be 12 subjects enrolled into the treatment phase of this study.  Additional 
subjects may be required to allow for screen failures  and i f a subject drops out before visit 5 
they will be replaced with a new subject.  If a subject drops out after visit 5 they will not be 
replaced.    Enrollment is not expected to be difficult due to the extensive experience of the 
investigator with this patie nt population and the strong Osteopetrosis Support group.   
Screening will focus on patients from known ADO2 kindreds.  Individuals should have either 
been diagnosed with Osteopetrosis and have a clinical phenotype and/or family history that 
is consistent with ADO2, have been told that they have an abnormally high bone density 
(>3SD about mean for age and sex), or a clinical presentation consistent with ADO2.    
3.4       STUDY ENDPOINTS  
Primary Efficacy Endpoint  
 
The primary efficacy endpoint is the difference in the subject‚Äôs observed change in bone 
markers (serum CTX and fasting urine NTX) over the treatment period (from Baseline to 
Week 14).  
Secondary Efficacy Endpoints  
‚Ä¢ Secondary endpoints will include analysis  of CTX and NTX over time while on a stable 
dose of Actimmune¬Æ and analysis of these markers after discontinuing drug to 
determine if patients rebound off drug.   
‚Ä¢ In addition, we will measure markers of bone formation (P1NP and bone specific 
alkaline phosp hatase) to test whether increased bone resorption from interferon 
gamma -1b therapy is coupled to increased bone formation.   
‚Ä¢ We will also obtain baseline measurements of bone density via DXA, spine QCT, and 
pQCT of the distal radius and tibia, as well as r etrospectively assessing the fracture 
rate in the 5 years prior to initiation of therapy (via a questionnaire with 
confirmation by review of radiographs films and/or reports) to facilitate a future 
longer term extension trial that would test whether long t erm treatment with 
Actimmune¬Æ decreases BMD and reduces fractures in ADO2 patients.  
Please see statistical section (section 8.0) for the statistical analysis plan.   
Safety Endpoints  
Adverse event (AE) data will be presented by subject. Clinical laboratory  safety data and 
vital sign data will be summarized by subject with descriptive statistics for Baseline, post -
dose, and change from Baseline to post -dose values. Physical examination findings will be 
listed by subject. AEs will be summarized by categories and grades. Counts and 95% 
Prot ocol Version 3  8 August 2 016 11 
 
 Clinical  Toxicity  ACTIMMUNE  
CGD (n=63)  Placebo  
CGD 
(n=65)  Fever  52 28 
Headache  33 9 
Rash  17 6 
Chills  14 0 
Injection  site erythema or  tenderness  14 2 
Fatigue  14 11 
Diarrhea  14 12 
Vomiting  13 5 
Nausea  10 2 
Myalgia  6 0 
Arthralgia  2 0 
Injection  site pain  0 2 
 Agresti -Coull confidence intervals will be calculated.  
The percentage of subjects with baseline nephrocalcinosis will be summarized using 
descriptive statistics along with degree of nephrocalcinosis.  Individual subjects 
developm ent of new nephrocalcinosis or worsening of existing nephrocalcinosis (identified 
by increasing grade) will be listed as an AE.  
3.5   ONGO ING SAFETY REVIEW 
All collected safety data including adverse events, safety test  results and changes in 
concomitant medications  will be reviewed by the principal investigator or designated 
physician sub investigator  in a timely fashion . Study nurses will review the results  for 
abnormal results as soon as received and if necessary contact the physician immediately.   
A data and safety monitoring board (DSMB) will be established to monitor the study.  This 
DSMB will be approved by the IRB prior to enrollment in the study is s tarted.  The DSMB 
will review data twice a year.  The DSMB will have authority to stop the trial for safety 
reason or to modify the trial if necessary for safety issues .  Due to the small study population 
and short study duration the DSMB will not be doing  interim analysis for effectiveness .   
3.6    STUDY  RISKS 
Risks of T aking Actimmune  
The following data on adverse reactions are based on the subcutaneous administration of 
ACTIMMUNE at a dose of 50 mcg/m2, three times weekly, in patients with Chronic 
Granulomatous Disease (CGD) during an investigational trial in the United States and 
Euro pe. 
The most common adverse events observed in patients with CGD are shown in the following 
table  (from product insert) : 
Percent of Patients  
 
 
 
 
  
 
 
 
 
 
 
 
Miscellaneous adverse events , which occurred infrequently in patients with CGD and may 
have been related to underlying disease included back pain (2 percent versus 0 percent), 
abdominal pain (8 percent versus 3 percent) and depression (3 percent versus 0 percent) 
Prot ocol Version 3  8 August 2 016 12 
 
 for ACTIMMUNE and pla cebo treated patients, respectively  (product label) . 
Similar safety data were observed in 34 patients with severe malignant Osteopetrosis.  
Radiation   
Subjects will be exposed to radiation as part of the protocol testing.  The protocol will be 
approved by I ndiana University Radiation Safety Committee prior to enrollment.  The 
informed consent will provide subjects information about the risks of additional radiation 
exposure above what would be considered standard of care for ADO2 subjects.   
Risk of  Blood Draws 
The risks that  can occur with venipuncture  include  discomfort, bruising, feeling faint or 
passing out, and infection.  To reduce the likelihood of complic ations from blo od draws, only 
trained phlebotomi sts or nurses will draw  blood at the study visits using clean technique . 
Loss of Confiden tiality 
There is the unl ikely chance that h ealth information is viewe d by someone  outside the 
research team who is not  authorized to see health info rmation.  How ever, standard 
procedures to ensure that this  does not happen will be  follo wed. 
3.7 STUDY  BENEFITS    
The major potential benefit to the subject is that the treatment may result in increased bone 
resorption, which may reduce disease burden by reducing bone fragility and, thereby, 
fracture risk.  Additionally, treatment may reduce the risk of infection, par ticularly 
osteomyelitis, and may improve hematopoietic marrow space, resulting in less anemia, 
pancytopenia, and/or extra medullary  hematopoiesis.   
ADO2 is an osteosclerotic disorder due to defective bone resorption.  There is wide 
variation in disease se verity, but most affected individuals experience fractures with almost 
half of affected adults experiencing hip or femur fractures.  Other manifestations include 
visual loss, osteonecrosis and/or osteomyelitis, and bone marrow failure.  Currently, there 
is no therapy for the disease;  however, studies in our ADO2 mouse model indicate that 
interferon gamma -1b may be effective in treating the human disease.  Successful completion 
of the proposed study will provide evidence that administration of Actimmune¬Æ induces 
osteoclastic bone resorption in ADO2 patients, a critical first step to determining whether 
the drug is a useful treatment for the disorder.  This study will provide critical data on 
feasibility and dosing and determine if a long -term study is indicat ed.  Interferon gamma -1b 
could be the first successful therapy for ADO2.  
3.8 INCLUSION  OF CHILDR EN 
ADO2 affects children as well as adults.  The study medication has been previously tested in 
children for other indications.  It is felt that the earlier the intervention can occur in disease 
process the increased chance of improved outcomes .   
 
Prot ocol Version 3  8 August 2 016 13 
 
 4.0 ‚Äì STUDY MEDICATI ON 
4.1 STRUCTURE  AND NOMENCLATURE  
ACTIMMUNE ¬Æ (Interfe ron gamma -1b) is a single -chain  polypeptide  containing  140 amino 
acids.  Production  of ACTIMMUNE is achieved  by fermentation  of a genetically  enginee red 
Escherichia   coli containing   the   DNA , which   encodes for the human p rotein.  
ACTIMMUNE  is a highly  purified sterile  solution  consisting  of non-covalent  dimers  of two 
identical  16,465 dalton  monomers;  with  a specific  activity  of 20 million  Inte rnational  Units 
(IU)/mg  (2x10 6 IU per 0.5 mL)  which  is equivalent to  30 million  units/mg  (product label) . 
4.2 PHYSICAL PROPERTIES 
ACTIMMUNE  is a sterile,  clea r, colorless  solution  filled  in a single -use vial for 
s u bc u t a ne ou s  i n j e c t i o n .  Each 0.5 mL of ACTI MMUNE  contains:  100  mcg  (2 
million  IU) of Interfe ron gamma -1b formulated  in 20 mg mannitol,  0.37  mg disodium 
succinate  hexahydrate , 0.14  mg succinic acid,  and 0.05  mg polysorbate  20 and Sterile  
Water  for Injection.  Note  that  the above  activity  is expressed  in Inte rnational  Units (1  million  
IU/50mcg). This is  equivalent  to what  was previously  expressed  as units  (1.5 million 
U/50mcg)  (product label) . 
4.3 MECHANISM OF ACTION 
Interferons bind to specific cell surface receptors and initiate a sequence of intracellular 
events that lead to the transcription of interferon -stimulated genes. The three major groups 
of interferons (alpha, beta, and gamma ) have partially overlapping bio logical activities  that 
include immunoregulation such as increased resistance to microbial pathogens and 
inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind to the alpha/beta 
receptor. Interferon -gamma binds to a different cell surfa ce receptor and is classified as 
Type 2 interferon. Specific effects of interferon -gamma include the enhancement of the 
oxidative metabolism of macrophages, antibody dependent cellular cytotoxicity (ADCC), 
activation of natural killer (NK) cells, and the e xpression of Fc receptors and major 
histocompatibility antigens  (product label) . 
In recessive osteopetrosis , the exact  mechanism(s)  by which  ACTIMMUNE  has a treatment  
effect has not been  established.  Changes  in supe roxide  levels during ACTIMMUNE  therapy  
do not predict  efficacy.   
Pharmacokinetics  
The intravenous,  intramuscula r, and subcutaneous  pharmacokinetics  of ACTIMMUNE  have  
been  investigated  in 24 healthy  male  subjects  following single -dose  administration  of 100  
mcg/m 2. ACTIMMUNE  is rapidly  clea red after intravenous  administration  (1.4 liters/minute)  
and slowly  absorbed  after intramuscular or  subcutaneous  injection.  After intramuscular or 
subcutaneous  injection,  the appa rent fraction  of dose  absorbed  was g reater  than  89%.  The 
mean  elimination  half-life after  intravenous administration  of 100  mcg/m 2   in healthy  
male  subjects  was  38 minutes. The mean  elimination  half -lives for subcutaneous  
dosing with  100  mcg/ m2  was  5.9 hours .  Peak  plasma concentrations , determined  by 
ELISA,  occur red approximately  7 hours  (0.6 ng/mL)  after subcutaneous  dosing.   Multiple  
dose subcutaneous   pharmacokinetic studies  were conducted  in 38 healthy  male  subjects.  
There was  no accumulation of ACTIMMUNE  after  12 consecutive daily  injections of 100   
Prot ocol Version 3  8 August 2 016 14 
 
 mcg/m 2 (package insert).     
4.4 STUDY  RELA TED INFO RMATION 
Contraindications  
ACTIMMUNE  is contraindicated  in patients  who  develop  or have  known hypersensitivity  
to interfe ron-gamma,  E. coli  derived  products , or any component of the product.  
Precautions  
Isolated  cases  of acute  serious hypersensitivity  reactions  have  been observed  in patients  
receiving  ACTIMMUNE . If such  an acute  reaction develops  the drug  should  be 
discontinued  immediately  and appropriate medical  therapy  instituted.  Transient  
cutaneous  rashes  have  occur red in some  patients  following  injection  but have  rarely 
necessitated  treatment interruption  (product label) . 
Actimmune  is a category C drug in pregnancy, there fore, female subjects who are pregnant or 
anticipating  pregnancy will not be enrolled and pregnancy tests will be done  for females of 
reproductive potenti al. 
 
5.0 ‚Äì ELIGIBILITY  
5.1 INCLUSION CRITERIA 
Subjects  must meet all of the follow ing criteria: 
1. Subject is diagnosed with clinically significant ADO2 as determined by the 
investigator . 
Individuals will be screened who have either been diagnosed with osteopetrosis and have a 
clinical phenotype and/or family history that is consistent with ADO2, have been told th at 
they have an abnormally high bone density (>3SD above mean for age and sex), or a clinical 
presentation consistent with ADO2.  Initial contact will be with members of ADO2 kindreds 
who have known disease.   
2. Provide written informed consent for competent  adults and f or minors p rovide 
written assent (if appropriate ) and written informed consent by a legally 
authorized representative after the nature of the study has been explained, and 
prior to any research -related procedures  
3. Ages 3 to 65 years inclusive .  
4. Willing to use reliable method of contraception [i.e. oral or patch hormonal 
contraceptives, intrauterine device, physical barrier methods, tubal ligation or 
hysterectomy, vasectomy (partner) or abstinence] throughout the study and for 
30 days after the l ast dose of study drug.  
5.2 EXCLUSION CRITERIA 
Subjects will be ineligible for study participation if they meet any of the following criteria.   
1.  Any unstable illness that in the investigator‚Äôs opinion precludes participation in 
the study.  
2. Serum calcium >10.6 mg/dl at screening.  
Prot ocol Version 3  8 August 2 016 15 
 
 3. eGFR using the MDRD equation in adults (or the modified Schwartz equation for 
children) of < 35 ml/min/1.73m2. 
4. Nephrocalc inosis on screening ultrasound Grade 3 or higher  [18] .  Subject s with 
grade 3 or higher nephrocalcinosis will be excluded because we anticipate that 
use of study dr ug will increase bone resorption, resulting in increased urinary 
calcium excretion, which could, potentially, lead to worsening nephrocalcinosis.  
The grading scale is listed below:  
0 = Normal  
1 = Faint hyperechogenic rim around the sides and tip of the medullary pyramids  
2 = More intense echogenic rim with echoes faintly filling the entire medullary pyramid  
3 = Intense echoes throughout the medullary pyramid  
4 = Solitary focus of echoes at t he tip of the medullary pyramid/nephrolithiasis   
5. Use of any investigational product (drug or device) within 30 days prior to 
randomization.  
6. Subject  reported  history of hepatitis C.  
7. A recent (past 5 years)  history of alcoholism or intravenous drug abuse.  
8. History of hypersensitivity to IFN -…£ or E. coli -derived products.  
9. History of liver disease  as evidenced by laboratory results at Screening  (aspartate 
aminotransferase [AST] or alanine aminotransferase [ALT]  >2x the upper limit of 
normal) , except when in the opinion of the investigator the liver disease is caused 
by extra medullary  hematopoiesis.  
10. Pregnant or nursing women or those who plan on becoming pregnant during the 
study.  
11. Preexisting cardiac conditions  including ischemia, congestive heart failure, or 
arrhythmia.   
5.3 EARLY  TERMINATION OF A STUDY  PARTICIPANT 
Treatment will stop and the subject will return for an exit visit if any of the following 
conditions occur:  
1. withdrawal of consent  
2. pregnancy (female participants)  
3. anaphylaxis requiring hemodynamic support (i.e. epinephrine and/or blood pressure 
medications) or mechanical ventilation  
4. any medically important event such as a concurrent illness or complications judged to 
significantly inc rease the risk of study therapy.  
5. any investigator judgment  
6. If any of the following dose -limiting toxicities occur:  
a. Increase in liver transaminases more than 5 times upper end of normal, total 
bilirubin ‚â•2.5 mg/d.  
b. Grade 3 or higher AE except as mentioned below. 
c. Develops Grade 2 or higher nephrocalcinosis, or symptomatic nephrolithiasis.  
 
Special circumstance: Grade 3 and 4 toxicity of absolute neutrophil count (ANC, includes 
neutrophils and bands) or platelet count :  
1. Marrow failure due to crowding from lack of bone resorption is part of the underlying 
disease of ADO, and there is no current effective approved therapy  for ADO to prevent or 
treat this.  Because of this, some subjects may have b aseline  values of ANC or platelets 
that are near the Grade 3 toxicit y level, prior to  study drug.   However, since there is no 
Prot ocol Version 3  8 August 2 016 16 
 
 effective therapy for ADO, and there is potential for interferon gamma 1b to improve 
marrow space and function if it proves effective to increase osteoclastic activity, subjects 
will be allowed to continue in study under the following conditions:  
a. If there is a decrease in absolute neutrophil count (ANC, includes neutrophils and 
bands) or platelet count to a Grade 4 toxicity (e.g. ANC < 500 or Platelets < 25k), 
we will hold study drug and monitor CBC with differential weekly until recovery 
to a grad e 3 toxicity level (ANC 500 ‚Äì 1,000; or platelets 25k -50k) and, after 
consultation with the patient and/or family (if a minor), restart at half the 
previous dose of interferon gamma 1b and continue to monitor CBC with 
differential weekly.   
b. If the patient remains above the target ANC after 2 weeks the investigators may 
consider re -challenge with the previous dose of interferon gamma 1b, with 
weekly CBC with differential monitoring.  
c. If toxicity reoccurs at the lowered dose we will again hold study drug and m onitor 
CBC with differential weekly until recovery to a grade 3 toxicity level (ANC 500 ‚Äì 
1,000; or platelets 25k -50k), and then can restart again with further lowering the 
dose by half again, or discontinue therapy, in consultation with the patient and/or  
family.   
d. If the patient remains above the target ANC after 4 weeks  the investigators may 
consider re -challenge with the previous dose of interferon gamma 1b, with 
weekly CBC with differential monitoring.  
 
Additional Considerations:  
 
1. There are potential for SAE during the study r elated to the underlying disease. These may 
include hospitalization or surgery for a fracture, or complications of anemia, bone marrow 
failure or infection, or vision loss.   Patients will discontinue study drug during h ospitalizations 
or surgeries, but will not be eliminated from the study except as described below, or at the 
investigator discretion based on severity of the incident and likelihood of relationship to study 
drug.  
2. Severe vision loss, which may possibly occ ur during the study period, is a part of the underling 
disease, usually presenting in children,  for which there is not currently any effective medical 
therapy to prevent. In fact the severe vision loss that occurs in a percentage of patients with 
this diso rder is only one of the reasons that this study is needed, because it may be possible 
with an effective treatment to prevent severe vision loss, but that cannot be determined except 
in future larger and longer trials, because the mechanism of vision loss i s thought to be optic 
nerve compression during skull growth. Although unlikely to occur during the short time 
frame of the study, if severe vision loss is detected clinically during this study, the individual 
patient will be stopped in the trial for the pu rposes of facilitating potential surgical treatment 
if deemed necessary by the treating clinician.  
3. A threshold of 25% of subjects having unexpected SAE‚Äôs would result in an expedited review 
by the DSMB for whether the study should be modified or completel y discontinued, except 
when the SAE is death or pregnancy having birth defect or for other SAE considered by the 
investigator (or DSMB) to represent a significant medical hazard. In the unlikely event of a 
subject death or the latter two events occur durin g the study, the study will be stopped and 
reviewed by the DSMB for whether the study should be discontinued.  Because there is some 
Prot ocol Version 3  8 August 2 016 17 
 
 risk of death with the underlying disorder, this will need to be assessed by the DSMB on a case 
by case basis.  
 
 
Subjects who stop study will be asked to return for a final early termination visit.   
 
6.0 ‚Äì STUDY P ROCEDURES  
6.1 I NFORMED CONSENT   
Consent/assents will be completed prior to any study related procedure.  Consents/assents 
can be obtained by designated staff as long as there is a physician investigator available for 
questions.   
The procedures planned will b e fully explained to the subj ect and/or family.  All 
consent/assent discussions will occur in a private room.  The investigational nature and 
objectives of the trial, the procedures involved, and their attendant risks and discomforts 
will be carefully explained to the potential subjec t and their questions answered. Potential 
subjects (or parents/guardians) will be informed that they have the right to decline 
participation in the study and that this decision will not impact their medical care. Subjects 
will also be notified of their rig ht to withdraw from the study at their (or their 
parent/guardian‚Äôs) choice, though recommendations for monitoring for subject safety will 
also be provided when appropriate.  
Assents will be obtained from all children age 7 to 18 if appropriate.  If a child is not 
appropriate for assenting then justification of this must be documented by a physician 
investigator.  If a child turns 7 during the conduct of the study then assent must be obtained 
at next visit.  It is also expected if a child turns 18 while on tr ial they will be asked to sign a 
full consent at next visit.  
6.2 P HYSICAL EXAM  
Physical exam will be completed by a ph ysician investigator.  Complete  physicals will be 
done  at screening and visit 1 (unless within 10 days of screening) 4 and 6. A brief phy sical 
exam can occur at visit 2 and 7.    
6.3 VITAL SIGNS   
Measured at all clinic visits after subject has had a chance to r est for approx. 5 mins.  Vital 
signs should be taken with subject sitting  with legs uncrossed .  Attempt should be made to 
use same ar m and cuff size for each visit.  Abnorma l results should be rechecked and 
physician notified  if vitals remain abnormal .   
6.4 A DVERSE EVENTS  
Subjects will be asked  about any changes in his/her health status at each site visit and 
phone call.  Adverse event s that occur within four weeks prior to Day 0 and prior to dosing 
on Day 0 will be considered baseline signs/symptoms. Adverse events or a worsening  of a 
condition listed as medical history that occur  after the dose on Day 0 through the end of the 
Prot ocol Version 3  8 August 2 016 18 
 
 study will be considered treatment -emergent adverse events (TEAEs). All SAEs that occur 
from the signing of informed consent through two weeks after study discontinuation will be 
recorded.  
All AE  and SAE info rmation will be reviewed by physician investigator for assessment.   
6.5 C ONCOMITANT MEDICATIONS  
Concomitant m edication data will be collected  from the subject, for all medication taken in 
the last 30 days .  This will include prescription, over the counter  medications and 
vitamins/supplements.  Subjects will be asked about any medication changes  at each site 
visit and phone  call, with a particular focus on pain medications.  Changes in the use of pain 
medicines will be analyzed to determine if subjects expe rience change in pain with therapy.  
This analysis may be complicated by the use of some pain medications as antipyretics 
(NSAIDs, acetaminophen).  Efforts should be made to determi ne the exact indication for use 
of pain medications such as NSAID and Aceta minophen.   
6.6 R ENAL ULTRASOUND  
Standard renal ultrasound will be complete d according to visit schedule.  Ultrasounds 
should be read locally and nephrocalcinosis graded according to the following grading scale:  
0 = Normal  
1 = Faint hyperechogenic rim around the sides and tip of the medullary pyramids  
2 = More intense echogenic rim with echoes faintly filling the entire medullary pyramid  
3 = Intense echoes throughout the medullary pyramid  
4 = Solitary focus of echoes at t he tip of the medullary pyramid/nephrolithiasis  
6.7 H EIGHT , WEIGHT AND BSA  
Height will be measured using a stadiometer that has routine calibration.  Weight will be 
measured on scales that are routinely calibrated.  All measurements should occur without 
shoes, pockets emptied and minimal clothing.  ( i.e. coats, heavy sweaters removed)  BSA will 
be calculated using the equation below  
ùêµùëúùëëùë¶  ùëÜùë¢ùëüùëìùëéùëêùëí  ùê¥ùëüùëíùëé =‚àöheight  (cm)x weight  (kg)√∑3600  
6.8 STUDY DRUG  
Subjects will receive subcutaneous doses of ACTIMMUNE TIW for a total of 14 weeks. The 
dose  of study drug will be determined using the subject‚Äôs body surface area (BSA) calculated 
at each clinic visit as:  
ùêµùëúùëëùë¶  ùëÜùë¢ùëüùëìùëéùëêùëí  ùê¥ùëüùëíùëé =‚àöheight  (cm)x weight  (kg)√∑3600  
To minimize side effects of the medication and improve tolerance we will start with a low 
dose and increase the dose according to a protocol developed by Devane et al [19] .  Dose 
escalation will be titrated as follows:  
‚Ä¢ Day 0  to day 6 : Subjects will receive  15 ¬µg/m2 SC TIW  
‚Ä¢ Day 7  to 14 : Subjects will receive 30 ¬µg/m2 SC TIW  
‚Ä¢ Day 15 -55: Subjects will receive 50 ¬µg/m2 SC TIW  
‚Ä¢ Day 56 (end of week 8) : Serum CTX will be assessed. Titration will occur by w eek 9 
based upon serum CTX  
Prot ocol Version 3  8 August 2 016 19 
 
 ‚Ä¢ Week 9 (approx. day 63) :  
o If CTX has increased by ‚â•25% above the mean of screening and baseline visits 
CTX values, the ACTIMMUNE dose stays at 50 ¬µg/m2 TIW  through week 14 . 
o If CTX is <25% above the mean of screening and baseline visits CTX values, 
then the ACTIMMUNE dose is increased to 100 ¬µg/m2 TIW  through week 14 . 
These doses are based on the current approved dose of Actimmune¬Æ for severe, malignant 
recessive osteopetrosis and animal studies [6] demonstrating that relatively high doses of 
mouse interferon gamma 1b increased bone resorption in the ADO2 mouse.  Data in 
melanoma patients showed that doses of 100 ¬µg /m2 TIW sub cutaneously (SC) were well 
tolerated (N=5), however daily dosing of either 100 ¬µg /m2 SC (N=5), 100 ¬µg /m2 IM (N=10), 
or 250 ¬µg /m2 IM (N=5) resulted in suppressed absolute neutrophil count, and at the highest 
dose increased liver enzymes  [20] .  Their data also suggested that monocyte activation 
returned to normal after 72 hours of dosing, supporting the need for TIW dosing.   
Dose reductions will be allowed on a case -by-case basis to manage subsequent drug -related 
adverse events (AEs).  If, in the opinion of the investigator, severe reactions occur during 
dose escalation, the dose will be reduced to the previous dose level or will be interrupted 
until the adverse event resolves and then restarted at the previous or a lower dose level.  
Additionally, the dose can be reduced based on laboratory values.  For example, we 
anticipate that the calcium/creatinine ratio will increase on drug due to increased bone 
resorption  (the goal of therapy).   Subject s will be encouraged to have  high  fluid 
consumption (>2 L/day  for adults , >30ml/kg/day  for children)  and those subject s with 
urine calcium/creatinine ratios above 0.25 will be encouraged to consume a low calcium 
diet of  les s than half the age appropriate RDA.  However, if either fasting  random  or 24 hour 
urine calcium/creatinine ratio increases above 0.5 the investigator can reduce the dose of 
study drug and/or put the subjects  on a lower calcium diet.   
Attempts should be ma de to keep dosing on a Monday, Wednesday, Friday dosing schedule.  
Missed doses can be taken the next day but two doses should not be taken in the same day.  
If a dose is missed and it is time for the next dose do not give 2 injections in one day.   If two 
days have passed since the last dose the dose will be skipped.  
Subjects should be instructed on how to give subcutaneous injections including drawing up 
the medication.  The optimal sites for injection are right and left posterior arm and upper 
leg.   
Stud y medication and supplies will be provided to subjects at clinic visits.  Vials  of 
ACTIMMUNE  must  be placed  in a 2 ‚Äì 8 ¬∞C (36 ‚Äì 46 ¬∞F) refrigerator immediately  upon  receipt  
to ensu re optimal  retention  of physical  and biochemical integrity .  DO NOT  FREEZE.  Avoid 
excessive  or vigo rous agitation.  DO  NOT  SHAKE.  An unentered  vial of ACTIMMUNE  
should  not be left at room  temperatu re for a total  time  exceeding  12 hours  prior  to use.  
Vials exceeding  this time  period  should  not be returned to the refrigerator; such  vials  
should  be marked do not use . Vials are single do se vials and should be marked used  after 
one use.   
Vials should be provided to subject with cooler and gel packs sufficient to keep 
refrigerated during transit home.  Subjects should also be provided with syringes, needles, 
alcohol wipes and sharps containers.   
Study medication diary  
Subjects will be provided a dosing diary.  This should be used to note all doses given 
Prot ocol Version 3  8 August 2 016 20 
 
 including the dose, date and time.  This should also be used to record missing doses.   
Compliance  
 All vials used and unused should be returned with dosing diary at eac h study site visit.  
Subject compliance will be assessed based on dosing diary.  Compliance will be calculated:  
(Actual doses taken √∑ expected dose)*100= percent compliant  
6.9       LAB COLLECTION  
Venous  blood  sampl es will be  collected by the experienced study staff  from each subject 
using clean  techniqu e. Aliquots of blood  will be  sent for laboratory tests described in 
schedule of events .  
Blood should be collected with the subjects in a fasting state with nothing but water 8 hrs 
prior to the draw.  
Urine NTX should be from the second morning urine.  Subject should void upon rising from 
bed and discard .  The sample should then be collected fr om the next void.   
6.10     RADIOGRAPHS  
Skeletal survey radiographs  
This should include anterior/posterior (A/P)  and lateral cervical, thoracic and lumbar 
spines, swimmers view, A/P  upper and lower ribs, pelvis, A/P  femurs, A/P  humer i, lateral 
skull.  
Duel Energy absorptiometry  (DXA)  
This  will measure lumbar spine, total body  (total body minus head for children <18),  total 
hip and femoral neck. Bone density testing is being done  to document skeletal phenotype 
and to provide baseline if subjects c ontinue in possible extension.   
Spine QCT  with V olumetric Spine BMD  
This will be done per standard procedure  for the radiology department .  This will only be 
done in subjects 10 and older.   
pQCT of Radius and Tibia  
 This  will be done according to standar d procedure.  This will only be done on subjects 5y/o 
and over.  pQCT will be used to assess cortical and trabecular bone sites at the  radius and 
tibia to provide baseline evidence of the disease phenotype and to follow into possible 
extension study .  Tomo graphic images of the distal (4% of bone length from distal end) and 
diaphyseal (66% of bone length from distal end) radius and tibia will be acquired with a 
Stratec XCT -3000 pQCT machine  [21-24]. Standardized segmenting and thresholding 
algorithms will be used to acquire cortical and trabecu lar bone properties at the diaphyseal 
and distal sites, respectively. Measures will include vBMD, BMC, total area, cortical area, 
average cortical thickness, and periosteal and endosteal perimeters. The polar strength -
strain index (SSI) and bone strength i ndex (BSI) will be determined at the diaphyseal and 
distal sites, respectively [25] . 
Osteopetrosis is a disease of incredibly dense and thickened cortical bone, thus the 
quanititative assessment of trabecular bone density by QCT is a more accurate method for 
identifying the subtle or early changes of treatment which is paramount for this study.   
Prot ocol Version 3  8 August 2 016 21 
 
  
 
22 
 
 6.11 S TUDY VISIT SCHEMATIC   
Study Phase  Screening  Treatment Period  Follow -up 
Visit #  SV1 12 2 3 4 5 6 73 
Week   Baseline  2 4 8 11 14/ET  18 
Study Days (¬± visit window)  -30 to -1 days  Day 0  14 (¬± 3)  
days  28 (¬± 3)  
days  56 (¬± 5)  
days  77 (¬± 5)  
days  98 (¬± 5) days  126 (¬± 3) days  
In person visit to IU4 X X X  X  X X 
Informed consent  X        
Review of inclusion/exclusion criteria  X X       
Demographics and  medical history  X        
SF-36  X     X  
Safety Assessments          
Physical examination  X X X  X  X X10 
Vital Signs: blood pressure, pulse, temperature  X X X  X  X X 
Baseline sign/symptom9 X X       
Adverse Events9  X X X X X X X 
Prior/concomitant medications  X X X X X X X X 
Renal ultrasound  X       X11 
Study Medication          
Weight/height, BSA5 X X X  X  X  
Educate /review  of dosing technique and dose 
level   X X  X    
Study medication d ose given at study visit6  X X  X    
Dispense study drug7  X X  X    
Drug compliance assessed by diary    X X X X X  
Dose escalation decision      X    
Laboratory Testing          
Serum pregnancy test 14 X        
Urine pregnancy test 14  X X X X X X X 
Genotype (not required for enrollment)   X       
Efficacy assessments:  
Resorption marker testing  -C-telopeptide 
[CTX], NTX, Tartrate resistant acid 
phosphatase type5b [TRAP5b])  X X X X X X X X 
  Formation marker Testing (bone specific 
alkaline phosphatase [BAP], type 1 
procollagen [P1NP])  X X X X X X X X 
  RANKL, OPG, CK -BB (all batched and 
measured at the end of the study)   X   X  X  
Clinical laboratory evaluation  
(hematology, chemistry, PTH , Vit D 
1,25(OH) 2, urinalysis)  X X X X X X X X 
Fasting Urine : Calcium  & Creatinine  X X X X X X X X 
IFN Œ≥ level prior to dose Day1; 6 hours post 
dose V1, V2 and V4   X X  X  X  
IFN Œ≥ immunogenicity testing (prior to dosing 
except safety visit)15  X X X X  X X 
23 
 
 Radiology Testing          
Skeletal survey (radiographs)  X        
  Dual energy X -ray absorptiometry    
  (DXA) lumbar spine, total body,  
  total hip and femoral neck8 X        
Spine QCT13 X        
pQCT of radius and tibia 12 X        
spine volumetric BMD by QCT13 x        
1  Screening procedures can take place over more than one day/clinic visit provided consent/assent is obtained first and all assessments are completed within the de signated window.  
2 On Day 0 (Baseline), subjects will receive the first dose of study drug while in the clinic; however, Baseline a ssessments will be performed prior to dosing.  
3 Eligible subjects completing 14 weeks of treatment may enroll in a long -term extension study at week 14 visit.  
4   Subjects and/or caregivers will be contacted by email or phone to monitor safety and dosing logistics on a weekly basis through Week 14.  
5 Height and weight will be measured at Screening and then at all treatment visits to determine BSA and dose.  
6 Dosing on Day 0 and Weeks 2, 8 and 14 will be performed at the clinic. Starting dose on Day 0 will be 15 mcg/m2 for 7 days (Week 1), then escalated to 30 mcg/m2 for 7 days (Week 2). At the 
Week 2 visit, subjects will be dosed at 50 mcg/m2 in the clinic.  If tolerated, subjects will continue on this dose until Wee k 8. At the Week 8 visit the dose ma y be escalated to 100 mcg/m2 until Week 
14. All other doses will be administered at home before bedtime on a three day a week (TIW) schedule.  
7 Subjects will be given a 2 week supply of study drug on Day 0.  At Week 2 visit, subjects will be given six week  supply. At Week 8 visit, subjects will be given a 6 week supply of study drug.  
8    Baseline values will be used to measure efficacy in subjects rolling over into the long -term extension study.   
9   Any change in health status including any new signs and  symptoms that occur after consent but  prior to Day 0 and prior to dosing on Day 0 will be considered baseline signs/symptoms. Adverse 
events occurring or worsening after the dose on Day 0 through the end of the study will be considered treatment -emergent adverse events (TEAEs). All SAEs that occur from the signing of informed 
consent through two weeks after study discontinuation will be recorded.  
10 Brief physical examinations will be performed at the Week 2 and Follow -Up Safety Visits; all other examinati ons will be complete physical examinations.  
11 If a subject  undergoes early termination from the study after week 6, then a renal ultrasound will be included during an early termination  visit.  
12 competed only if subject ‚â•5 years old  
13 completed  only if  subject is ‚â• 10 years old.  
14 for women of child bearing potential.  
15.  If a subject tests positive for anti -drug antibodies (ADA), he/she will be followed until ADA levels revert to baseline.    
 
Prot ocol Version 3  8 August 2 016 24 
 
 6.12 VISIT DETAILS 
Scree ning (-30 to -1) 
Screening can occur over more than one day as long as the consent processes is completed 
first.   
Screening will include all of the following:  
 Consent  
 Review of inclusion/exclusion  
Collection of demographics, medical history , prior and curre nt medications and 
baseline signs and symptoms.  
 Physical exam, vitals, height and weight  
 Renal ultrasound  
 Skeletal survey  
 DXA  
 Spine QCT  
 pQCT  
Blood testing  will include: pregnancy, hematology, Chemistry, PTH, Vit D 1,25, CTX, 
TRAP5b , Bone specific alk phos  (BAP) , P1NP  
Urine tests  (fasting)  will include: NTX, UA , calcium, creatinine  
Visit 1 Baseline (day 0)  
 Review of inclusion/exclusions  
 Physical exam, vita ls, height and weight  
 Review of baseline symptoms and concomitant  medication  
 Educate on  dosing  technique and dose level  
 Study medication dose  given (1st dose)  
Revi ew of adverse events (acute events as first dose will be given on this day)  
 SF-36  
 Dispensing of study medication for 2 weeks  
 Dispense dosing diary  
Blood testing will include: Genotype, CTX, TRAP5b, BAP, P1NP, RANKL, OPG, CK -BB, 
hematology, Chemistry, PTH , Vit D 1,25 (OH) 2 ,  IFN Œ≥  pre dose immunogenicity  
IFN Œ≥ level predose and 6 hours  post dose.  
Urine test will include: pregnancy, NTX, UA , calcium, creatinine  
Visit 2 week 2/ day 14  (¬±3 day)  
Vitals, height and weight  
 Revi ew of adverse events and concomit ant medication  
 Review  of dosing and injection procedures  
 Study medication dose  given  
 Dispensing of study medication for 6 weeks  
 Dispense dosing diary  
Collect all used study medication  
 Assess study medication compliance after diary review  
Blood testing will include: CTX, T RAP5b, BAP, P1NP, hematology, Chemistry, PTH , Vit 
D 1,25 (OH) 2, IFN Œ≥  immunogenicity  
IFN Œ≥ level predose and 6 hours post dose.  
Urine test will include: pregnancy, NTX, UA, calcium, creatinine  
Prot ocol Version 3  8 August 2 016 25 
 
 Visits 3 week  4 (¬±3 day)  and visit 5 week 11  (¬±5 day)  
These visits may be completed over the phone after blood work has been at a local central 
lab collection location.  
 Review of adverse events and concomitant  medication  
 Assess study medication compliance after diary review  
Labs to be collected at local collection site: Blood testing will include: CTX, TRAP5b, 
BAP, P1NP, hematology, Chemistry, PTH , Vit D 1,25 (OH) 2 
Urine test will include: pregnancy , NTX, UA, calcium, creatinine  
IFN Œ≥  immunogenicity  at Week 4  
Visit 4 week 8  (¬±5 day)  
 Physical exam, vitals, height and weight  
 Review of adverse events and concomitant  medication  
 Review of dosing and injection procedures  
Dose escalation decision  
 Study medication dose  given  
Collect all used study medication   
Dispensing of study medication for 6 weeks  
 Dispense dosing diary  
Assess study medication compliance after diary review  
Blood testing will include: CTX, TRAP5b, BAP, P1NP, RANKL, OPG, CK -BB, hematology, 
Chemistry, PTH , Vit D 1,25 (OH) 2, IFN Œ≥ immunogenicity  
IFN Œ≥ level predose and 6 hours post dose.  
Urine test will include: pregnancy, NTX, UA, calcium, creatinine  
Visit 6 week 14 or early termination  (¬±5 day)  
  Physical exam, vitals, height and weight  
 Review of adverse events and concomitant  medication  
SF 36  
 Assess study medication compliance after diary review  
Collect all study medication supplies  
Blood testing will include: CTX, TRAP5b, BAP, P1NP, RANKL, OPG, CK -BB, hematology, 
Chemistry, PTH , Vit D 1,25 (OH) 2 , IFN Œ≥  immunogenicity  
IFN Œ≥ level predose.  
Urine test will include: pregnancy, NTX, UA, calcium, creatinine  
If early term after 6 weeks renal ultrasound should also be done.  
Visit 7 week 18 Follow up  (¬±3 day)  
  Physical exam, vitals, height and weight  
 Review of adverse events and concomitant  medication  
 Renal ultrasound  
Blood testing will include: CTX, TRAP5b, BAP, P1NP, RANKL, OPG, CK -BB, hematology, 
Chemistry, PTH , Vit D 1,25 (OH) 2 , IFN Œ≥  immunogenicity  
IFN Œ≥ level predose.  
Urine test will include: p regnancy, NTX, UA , calcium, creatinine  
6.13      RETENTION PLAN  
Participating subjects will be seen or contacted by phone (or email) at least weekly to query 
regarding any concerns the subject may have regarding participation or adverse events, and 
Prot ocol Version 3  8 August 2 016 26 
 
 to improve retention and compliance. If a subject  is having problems wi th flu like symptoms, 
which may affect participation in the study, dosage adjustments may be made.  
In addition to aid in retention, two study visits may be done over the phone with a  local 
collection of blood and urine for laboratory assessments, in order to be more convenient for 
the subject . However, the Screening, Day 0, week 2, week 8, week 14 and week 18 visits 
must occur at the Indiana University School of Medicine  
7. 0 - REPORTING OF ADVERSE E VENTS OR UNANTICI PATED 
PROBLEMS INVOLVING RISK TO PARTICI PANTS OR  OTHERS 
7.1       UNANTICIPATED  PROBLEMS 
In the  event of physical inju ry resulting  from the  participation in this research, necessa ry 
medical treatment will be  provid ed and billed as part  of the subjects  medical expenses.  
Costs not covered by the subject‚Äôs  health c are insurer will be  the subje ct‚Äôs responsibilit y.  
Also, it is the subject‚Äôs responsibility to determine  the extent of health c are coverage.  There 
is no program in pla ce for other mone tary compen sation for such injuri es. How ever, the  
subject has  not given up any legal rights or benefits to which he/she is otherwise entitled.   
7.2 DATA  SAFETY MON ITORING BOARD  
An external and indep endent Data Safety Monit oring Board (D SMB) from the MARCH 
(Midwes t Area Research Consortium  for Health) will moni tor this study  and be p rovid ed 
with i nformation about  subjects ‚Äô outcom es and adverse events every six months . 
The study team  will re view the data for  safety and b enefits on a continual basis .  The team 
will then  generate a summ ary report based upon that intern al review including  a decision to 
stop do se escalation . This report will be  provid ed to our primary MARCH DSMB contact, 
who will re view at their next  full D SMB meeting. All adverse events related to d ose limit ing 
toxicity will be  reported, as they  occur, to the MARCH DSMB. 
A threshold of 25% of subjects having unexpected SAE‚Äôs would result in an expedited 
review by the DSMB for whether the study should be modified or completely discontinued, 
except when the SAE is death or pregnancy having birth defect or for other SAE considered 
by the investigator (or DSMB) to represent a significant medical hazard. In the unlikely 
event of a subject death or the latter two events occur during the study, the study will be 
stopped and revie wed by the DSMB for whether the study should be discontinued.  Because 
there is some risk of death with the underlying disorder, this will need to be assessed by the 
DSMB on a case by case basis.  
7.3 ADV ERSE EVENTS 
An ad verse event is defined as any unintend ed or abnormal clinical observation th at is not of 
benefit to the subject .  Either  the condit ion was not present prior to exposure to test 
medi cation, or it has worsened in inten sity or frequency following exposure to test 
medi cation.  Ad verse events will be  graded according to  the N ational Cancer Institute ( NCI) 
Common Termino logy Criteria v4.0 
(CTCAE ):http://ctep.cancer.gov/p rotocolDevelopmen t/electronic_ appli cations/ctc.htm  
 
Prot ocol Version 3  8 August 2 016 27 
 
 The Sponsor -Investigator will be responsible for fulfillment of safety reporting obligations 
to authorities, investigators, and Ethic Committees according to applicable regulations, 
including reporting to applicable competent authority.  
  
Principal inv estigators (PI) must report to the IRB as soon as p ossible, but in  all cases within 
5 working  days from notification any event that appears on the  List of Events that Require 
Prompt Reporting  to the IUPUI IRB. 
 
List of Events that  Require Prompt Reporting to  the I UPUI IRB: Any of the follo wing: 
‚ùñ Event (including  adverse events, injuries, side effects during the research study), 
which in the opinion of the PI 
‚Ä¢ caused harm to one or more subjects or others, or placed one or more subjects 
or others at increased risk of harm; A ND 
‚Ä¢ was unexpected; AND 
‚Ä¢ was related to  the rese arch procedures or study medications  
 
Note:  After the study is closed with the IRB, these events should only  be reported if they  are 
profound  or they  demonstrate long-term risks that would neces sitate notifying  subjects. 
‚ùñ Protocol deviation/v iolation  (as defined  und er this policy and o n-site only)  
‚ùñ Change to the p rotocol taken without p rior IRB review to elimin ate apparent 
immed iate hazard to a research subject (e.g. purposeful and for subject safety) (on-
site onl y) 
‚ùñ Complaint of a subject that indicates une xpected r isks, or complaint that cannot  be 
resolved by the research team (on-site onl y) 
‚ùñ Inter im findings and  safety monit oring re ports that ind icate an un expected change to 
the risks or pot ential b enefits of the research, in te rms of severity or  frequency 
‚ùñ Public ation in  the l itera ture that indi cates an un expected change to the risks or 
poten tial benefits of the rese arch 
‚ùñ Change in FDA labeling or withd rawa l from mark eting  of a drug, device, or biologic  
used in a research study  
‚ùñ Noncompli ance (as defined in this  policy and on -site only) 
 
Unanticipated problems  involving  risk to vo lunte ers or others, ser ious adverse events 
related to  particip ation in the study, and a ll vol unteer deaths related to  particip ation in the 
study  should be p romp tly reported to study staff by phone  (317-948 -8346 ), by email 
(marihart@ iu.edu),  or by facsimile  (317 -948-2254 ). 
 
The principal investigator mu st compl ete the FDA  MedWatch 3500a form and assess the 
relationship to study treatment and send the initi al complet ed MedWatch fo rm within  24 
hours. The investigator must then ensure that the form is accurately and fully complet ed 
with follow-up in formation wi thin 2 to 3 calendar  days for  deaths or life-threatening  events 
and 5 calendar da ys for other serious  adverse events. The original and the dupli cate copies 
of the FDA  MedWatch f orm and the f ax confirmation  sheet must be kept with the case report 
forms at the study  site. 
Prot ocol Version 3  8 August 2 016 28 
 
  
Follo w-up information should describe whether the event has  resolved or continues, if and 
how it  was treated, whether  the blind was broken or not, and whether the subject  continued  
or discontinu ed study particip ation.  The MedWatch fo rm sheet must be r etained at Indiana 
Univ ersity. Pregnancy follow-up should d escribe the outcome  of the pr egnancy, including 
any volunt ary or spontaneous terminat ion, d etails of the bi rth, and the p resence or absence 
of any congenital abnormalities or birth d efects. 
8. 0 ‚Äì STATI STICAL CONSIDER ATIONS 
The sample size N=12 is justified based on the following hypothesis testing: H0: ŒîCTX(%)=0 
versus Ha: ŒîCTX(%)‚â•25% using one -sample Student‚Äôs t -test. Consequently, we will have a 
power of 80% at type I error level 0.05 if the corresponding standard deviat ion is no bigger 
than 28.1%, which is considered as obtainable from our previous experiences.    
Percent changes in bone markers (serum CTX and fasting NTX)  from baseline, denoted as 
Œî‚Äôs, will be summarized as means and standard deviations (SDs) and be te sted as H0: Œî=0 
versus Ha: Œî‚â†0. This endpoint will be assessed on all subjects tolerating at least 30 ug/m2 
TIW.  
Longitudinal profiles of bone turnover markers will be evaluated by linear mixed effects 
models. Time will be included as both a continuous var iable and a categorical variable to 
account for potentially nonlinear effects. Graphs of individual subject curves of CTX and 
NTX/creatinine ratios and other bone turnover markers over time will also be generated.  
CTX and NTX/creatinine concentrations duri ng dose escalation, at peak dose, and at study 
end will be analyzed by repeated measure analysis of variance to evaluate dose response 
and to determine whether bone resorption markers are stable once final dose therapy is 
achieved.  
Fasting urine calcium/cr eatinine ratio between baseline and while on drug, which are 
anticipated to increase with therapy, will be analyzed by linear or nonlinear mixed effects 
models, depending the distribution of the ratio.   
Baseline fracture rates (fractures per year in the 2 years prior to the start of the study) and 
the fracture rates in the year while on therapy for subjects enrolled in the long -term 
extension study will be summarized by descriptive statistics. We do not expect that there 
will be enough statistical pow er to conduct a formal hypothesis test for these 12 subjects 
alone.  
Change from baseline in DXA in subjects enrolling in the long -term extension study will be 
measured at the end of one year of therapy in the extension study (primary endpoint for the 
exten sion study). DXA changes will be summarized by mean (SD) and 95% confidence 
interval . 
The proportions of subjects obtaining ‚â•25% bone marker changes from baseline will be 
estimated with their 95% Agresti -Coull confidence intervals.  
Baseline characteristics  will be summarized by descriptive statistics.  
Subjects may drop out for a variety of reasons including expected or unexpected AEs of the 
therapy.  If a subject drops out before visit 5 they will be replaced with a new subject.  This 
decision is based on h aving adequate data on the primary outcome of bone turnover 
Prot ocol Version 3  8 August 2 016 29 
 
 markers to interpret the study results.  If a subject drops out after visit 5, they will not be 
replaced.  
9. 0 ‚Äì PRIVACY /CONFIDENTIALIT Y ISSU ES 
Data so urces will in clude  paper and electronic  medical records and test results. Data will be  
recorded on pap er, desktop com puters, and laptop compute rs. The Principal Investigators, 
Research Coordinators, Co- Investigators, Biostatistics, and Gov ernment al Agencies will 
have acce ss to the indiv idually identifiable data. This data will be  safeguarded by lo cking  
storage cabinets  and o ffice doors, keeping i nformation in areas with limit ed public  acce ss, 
password protecting compute rs and files, and regular back-ups of electronic d ata. Data will 
be retained indefinite ly. When confidential d ata needs to be  discarded, paper records will be  
shredded, CD‚Äôs and d iskettes will be destroyed, and data will be  permanently d eleted from 
computer s. When possible, only d e-identified data will be shared.  If identifiable data will be  
shared,  it will be do ne by fax in a  secured area, on a  shared drive with password protection,  
or by personal d elivery by authorized research pe rsonnel. 
10.0 FOLLOW -UP AND RECORD RETENT ION 
10.1 SUBJECT COMPENSATION 
Subjects will be reimbursed for travel (driving) and parking to study visits and will receive an 
honoraria for each on site visit as follows: $100 for the first visit; $40 for sub sequent visits; and 
$25 for local  sample collection.  
10.2 RECORD RETENTION 
All records will be kept for a minimum of 15 years . 
11.0 ‚Äì REFERENC ES CITED 
1. Cleiren, E., et al., Albers -Schonberg disease (autosomal dominant osteopetrosis, type II) 
results from mutations in the ClCN7 chloride channel gene.  Hum Mol Ge net, 2001. 
10(25): p. 2861 -7. 
2. Waguespack, S.G., et al., Chloride channel 7 (ClCN7) gene mutations and autosomal 
dominant osteopetrosis, type II.  J Bone Miner Res, 2003. 18(8): p. 1513 -8. 
3. Johnston, C.C., Jr., et al., In vivo measurement of bone mass in the radius.  Metabolism, 
1968. 17(12): p. 1140 -53. 
4. Waguespack, S.G., et al., Autosomal dominant osteopetrosis: clinical severity and 
natural history of 94 subjects with a chloride channel 7 gene mutation.  J Clin Endocrinol 
Metab, 2007. 92(3): p. 771 -8. 
5. Benichou, O.D., J.D. Laredo, and M.C. de Vernejoul, Type II autosomal dominant 
osteopetrosis (Albers -Schonberg disease): clinical and radiological manifestations in 42 
patients.  Bone, 2000. 26(1): p. 87 -93. 
6. Alam, I., et al., Interferon Gamma, but not Calcitriol Improves the Osteopetrotic 
Phenotypes in ADO2 Mice.  J Bone Miner Res, 2015.  
7. Key, L., et al., Treatment of congenital osteopetrosis with high -dose calcitriol.  N Engl J 
Prot ocol Version 3  8 August 2 016 30 
 
 Med, 1984. 310 (7): p. 409 -15. 
8. Alam, I., et al., Generation of th e first autosomal dominant osteopetrosis type II (ADO2) 
disease models.  Bone, 2014. 59: p. 66 -75. 
9. Key, L.L., Jr., et al., Long -term treatment of osteopetrosis with recombinant human 
interferon gamma.  N Engl J Med, 1995. 332 (24): p. 1594 -9. 
10. Madyastha , P.R., et al., IFN-gamma enhances osteoclast generation in cultures of 
peripheral blood from osteopetrotic patients and normalizes superoxide production.  J 
Interferon Cytokine Res, 2000. 20(7): p. 645 -52. 
11. Kamolmatyakul, S., W. Chen, and Y.P. Li, Inter feron -gamma down -regulates gene 
expression of cathepsin K in osteoclasts and inhibits osteoclast formation.  J Dent Res, 
2001. 80(1): p. 351 -5. 
12. Fox, S.W. and T.J. Chambers, Interferon -gamma directly inhibits TRANCE -induced 
osteoclastogenesis.  Biochem Bi ophys Res Commun, 2000. 276 (3): p. 868 -72. 
13. Cheng, J., et al., Molecular mechanisms of the biphasic effects of interferon -gamma on 
osteoclastogenesis.  J Interferon Cytokine Res, 2012. 32(1): p. 34 -45. 
14. Darden, A.G., et al., Osteoclastic superoxide pr oduction and bone resorption: stimulation 
and inhibition by modulators of NADPH oxidase.  J Bone Miner Res, 1996. 11(5): p. 671 -
5. 
15. Rodriguiz, R.M., L.L. Key, Jr., and W.L. Ries, Combination macrophage -colony 
stimulating factor and interferon -gamma admin istration ameliorates the osteopetrotic 
condition in microphthalmic (mi/mi) mice.  Pediatr Res, 1993. 33(4 Pt 1): p. 384 -9. 
16. Gao, Y., et al., IFN-gamma stimulates osteoclast formation and bone loss in vivo via 
antigen -driven T cell activation.  J Clin Inv est, 2007. 117 (1): p. 122 -32. 
17. Kim, J.W., et al., Effect of interferon -gamma on the fusion of mononuclear osteoclasts 
into bone -resorbing osteoclasts.  BMB Rep, 2012. 45(5): p. 281 -6. 
18. Patriquin, H. and P. Robitaille, Renal calcium deposition in children: sonographic 
demonstration of the Anderson -Carr progression.  AJR Am J Roentgenol, 1986. 146 (6): 
p. 1253 -6. 
19. Devane, J.G., M.L. Martin, and M.A. Matson, A short 2 week dose titration regimen 
reduces the severity of flu -like symptom s with initial interferon gamma -1b treatment.  
Curr Med Res Opin, 2014. 30(6): p. 1179 -87. 
20. Maluish, A.E., et al., The determination of an immunologically active dose of interferon -
gamma in patients with melanoma.  J Clin Oncol, 1988. 6(3): p. 434 -45. 
21. Moyer -Mileur, L.J., J.L. Quick, and M.A. Murray, Peripheral Quantitative Computed 
Tomography of the Tibia: Pediatric Reference Values.  Journal of Clinical Densitometry, 
2008. 11(2): p. 283 -294.  
22. Ashby, R.L., et al., A reference database for the Stratec  XCT -2000 peripheral 
quantitative computed tomography (pQCT) scanner in healthy children and young 
adults aged 6 ‚Äì19 years.  Osteoporosis International, 2009. 20(8): p. 1337 -1346.  
23. Swinford, R.R. and S.J. Warden, Factors affecting short -term precision of 
musculoskeletal measures using peripheral quantitative computed tomography (pQCT).  
Osteoporos Int, 2010. 21(11): p. 1863 -70. 
24. Warden, S.J., et al., Racial differences in cortical bone and their relationship to 
biochemical variables in Black and White ch ildren in the early stages of puberty.  
Prot ocol Version 3  8 August 2 016 31 
 
 Osteoporos Int, 2013. 24(6): p. 1869 -79. 
25. Kroger, H., et al., Bone densitometry of the spine and femur in children by dual -energy x -
ray absorptiometry.  Bone Miner, 1992. 17(1): p. 75 -85. 
 
 